Prescription Peptides: What They Are and How to Get Them

Key Takeaways

• Regulatory Status: As of April 2026, prescription peptides fall into two groups: FDA-approved compounds (semaglutide, tesamorelin, bremelanotide) with defined approved indications, and a set of GH-secretagogue peptides (sermorelin, CJC-1295, ipamorelin) that have historically been compounded under Section 503A but sit in a restricted regulatory position. CJC-1295, ipamorelin, and BPC-157 are on FDA's Category 2 bulk drug substances list — designated by FDA as ineligible for use in 503A compounding under the interim policy. Sermorelin's compounding eligibility depends on pharmacy API sourcing, and availability has changed materially in 2023–2026.
• Research Stage: FDA-approved compounds have completed Phase 3 RCTs; sermorelin has the most robust human data among compounded GH secretagogues (including its prior history as the FDA-approved Geref); CJC-1295 has limited Phase 1 human data (Teichman 2006); ipamorelin's published human data is more limited still; BPC-157 has preclinical data only with no completed randomized controlled human trials.
• Availability: Prescription only, through licensed providers and 503A compounding pharmacies; some compounds also available as branded FDA-approved products through conventional retail pharmacy
• How it works: A licensed practitioner evaluates the patient, establishes clinical rationale, and transmits a patient-specific prescription to a licensed compounding pharmacy for preparation and dispensing.
• What the evidence shows: FDA-approved peptides have the most robust evidence base, with Phase 3 randomized trials supporting their approved indications. Compounded GH secretagogues have varying levels of human evidence — strongest for sermorelin, limited for CJC-1295, and more limited still for ipamorelin. Research peptides obtained outside the prescription system have documented contamination and dose inaccuracy risks, and compounds on FDA's Category 2 bulk drug substances list (CJC-1295, ipamorelin, BPC-157) are not eligible for compounding under FDA's interim policy.

Peptide drugs are not a new category. Insulin — a 51-amino-acid peptide — has been in clinical use since 1921. A 2017 database analysis by Usmani and colleagues, published in PLOS ONE, catalogued a large catalog of FDA-approved peptide and protein therapeutics in the THPdb database — evidence that peptides are a well-established, actively regulated pharmaceutical drug class. Muttenthaler and colleagues, in a 2021 Nature Reviews Drug Discovery review, documented that synthetic peptides have comprised a growing share of FDA new molecular entity approvals over the past decade, with peptide therapeutics now representing a well-established class in the drug-discovery pipeline. What has changed in recent years is not the existence of prescription peptide therapy; it is the expansion of compounded peptide access through telehealth platforms and the simultaneous growth of an unregulated grey market that uses the same terminology to describe products with fundamentally different regulatory oversight and documented quality-control standards.

How Prescription Peptide Therapy Works

The prescription pathway

For a peptide compound to reach a patient as a prescription medication in the United States, three components must be in place. First, a licensed prescriber — an MD, DO, nurse practitioner, or physician assistant with authority in the patient's state — must evaluate the patient, review relevant clinical history and laboratory data, determine that the compound is appropriate for this specific patient, and document a clinical rationale. Second, the prescriber transmits a patient-specific prescription to a licensed 503A compounding pharmacy. Third, that pharmacy prepares the compound, follows USP <797> sterility assurance protocols for sterile preparations, verifies ingredient identity at receipt, and applies compound-specific quality controls (including additional end-product testing where required by the compound and preparation category) before dispensing the medication to the patient. Cabaleiro, in a 2021 analysis in International Journal of Pharmaceutical Compounding, confirmed that patient-specific prescriptions from licensed practitioners are the fundamental legal requirement for 503A compounding. Gianturco and Mattingly, in a 2021 analysis in Journal of the American Pharmacists Association, distinguished 503A patient-specific compounding from 503B outsourcing facilities — the 503A model is the pathway for individually prescribed compounded peptides.

What makes a prescription peptide legitimate

Qureshi and colleagues, in a 2014 review in Journal of Managed Care & Specialty Pharmacy, provided a foundational review of the sterile compounding regulatory framework — covering the legal and manufacturing standards that differentiate licensed compounding pharmacies from unregulated producers. Martin, in a 2018 paper in International Journal of Pharmaceutical Compounding, described USP 797 quality assurance and FDA inspection compliance for sterile compounding — including environmental monitoring, personnel testing, sterilization verification, and potency testing. Pritchett and colleagues, in a 2018 review in International Journal of Pharmaceutical Compounding on certification and accreditation standards for 503A pharmacies, documented the PCAB accreditation and USP compliance infrastructure that separates credentialed compounding pharmacies from noncompliant operations. A prescription compounded peptide has a documented chain of custody from licensed prescriber to licensed pharmacy to patient. A research peptide has none of these elements.

Prescriber accountability

Kircik and Siegel, in a 2023 review in Journal of Clinical and Aesthetic Dermatology, reviewed prescriber liability and documentation requirements in pharmaceutical compounding — the legal standards that prescribers must meet when writing any compounded medication order. These requirements include documentation of clinical rationale, patient-specific assessment, and the clinical basis for choosing a compounded formulation over an FDA-approved alternative where one exists. The Obesity Medicine Association's 2024 FAQ document, authored by Bays and colleagues in Obesity Pillars, called for regulatory clarity on compounded peptide prescribing — an indication that major medical societies are actively engaged in defining the appropriate prescribing standards for this compound class.

FDA-Approved Prescription Peptides

GLP-1 receptor agonists

The most widely prescribed peptide therapeutics in the United States are GLP-1 receptor agonists, all of which are FDA-approved and available through conventional retail and specialty pharmacies. Semaglutide (Ozempic for type 2 diabetes; Wegovy for chronic weight management; Rybelsus as an oral formulation) is a 7-amino-acid GLP-1 analog. A 2021 RCT by Wilding and colleagues in the New England Journal of Medicine, the STEP 1 trial, enrolled 1,961 adults with overweight or obesity and found that weekly subcutaneous semaglutide 2.4 mg produced a mean body weight reduction of 14.9% versus 2.4% with placebo over 68 weeks. Cardiovascular evidence followed: the SELECT trial published by Lincoff and colleagues in the New England Journal of Medicine in November 2023 showed semaglutide reduced major adverse cardiovascular events by 20% in 17,604 adults with overweight or obesity over a median follow-up of 33.4 months. Individual results vary. See the FDA-approved prescribing information for semaglutide for full indications, contraindications, and safety information. Superpower's semaglutide page provides the full clinical evidence summary. [Human RCT — FDA-approved indication]

Tesamorelin

Tesamorelin (Egrifta) is an FDA-approved synthetic GHRH analog prescribed specifically for HIV-associated lipodystrophy. A phase III RCT by Falutz and colleagues, published in the Journal of Acquired Immune Deficiency Syndromes in 2010, enrolled 273 HIV-positive patients and found a 10.9% reduction in visceral adipose tissue with tesamorelin versus 0.6% with placebo over 6 months. Dhillon, in a 2011 spotlight review in BioDrugs, summarized the FDA approval process and prescribing context for tesamorelin, documenting that its approval was based on this phase III data. Tesamorelin is available only as the FDA-approved Egrifta formulation; it is not routinely compounded under 503A. Off-label prescribing of Egrifta (outside HIV-associated lipodystrophy) is legal where a licensed prescriber documents clinical rationale, as with any FDA-approved drug, though payer coverage for off-label use is typically limited. Superpower's tesamorelin page covers the full regulatory and evidence context. [Human RCT — FDA-approved indication]

Bremelanotide (PT-141)

Bremelanotide (Vyleesi) is an FDA-approved melanocortin receptor agonist prescribed for hypoactive sexual desire disorder (HSDD) in premenopausal women. Mayer and Lynch, in a 2020 review in Annals of Pharmacotherapy, documented the FDA approval pathway and clinical evidence for bremelanotide, including the Phase 3 trials that established its efficacy for HSDD. The FDA-approved formulation is a subcutaneous auto-injector; some providers compound intranasal formulations, though these are not FDA-approved. Compounding an alternate-route formulation of an FDA-approved drug requires the prescriber to document a patient-specific clinical difference under Section 503A(b)(1)(D); it is not a blanket substitute for the approved subcutaneous formulation. Superpower's PT-141 page provides compound-level detail. [Human RCT — FDA-approved indication]

Compounded Prescription Peptides

Under FDA's interim 503A Bulks List policy, bulk drug substances fall into two categories. Category 1 substances are eligible for use in compounding under the interim policy. Category 2 substances are those for which FDA has identified significant safety concerns — compounding under the interim policy is not permitted. As of April 2026, the GH secretagogues CJC-1295 and ipamorelin are on Category 2. BPC-157 is also on Category 2. Sermorelin's compounding eligibility is nuanced and depends on API sourcing and pharmacy compliance rather than a blanket categorical status. The compound profiles below are provided for educational completeness; each compound's current regulatory status should be verified with the prescribing provider and compounding pharmacy at the time of any clinical decision.

Sermorelin

Sermorelin is a synthetic 29-amino-acid GHRH analog and one of the most commonly prescribed compounded peptides for adult GH insufficiency. Walker, in a 2006 review in Clinical Interventions in Aging, described sermorelin's prescribing context and clinical evaluation requirements, documenting that it stimulates endogenous GH release from the pituitary in a pulsatile pattern that approximates normal physiological secretion. Sigalos and colleagues, in a 2017 study in American Journal of Men's Health, reported IGF-1 increases in hypogonadal men receiving growth hormone secretagogue therapy, supporting the pituitary-stimulating mechanism as a favorable alternative to exogenous GH administration that preserves the natural pulsatile pattern and avoids the suppression of endogenous GH axis function associated with direct GH injection. Sermorelin is not FDA-approved for any current indication — the original FDA-approved formulation (Geref) was withdrawn from the commercial market — and its eligibility for 503A compounding depends on the specific pharmacy's API sourcing pathway (USP-NF compliance, FDA-registered API facility, or prior-approval pathway), not on prescriber rationale alone. Prescriber clinical documentation is necessary but not sufficient. [Compounded preparation; no current FDA-approved indication. Prescribing reflects the independent clinical judgment of the prescribing physician under 503A where compounding eligibility is established.]

CJC-1295 and ipamorelin

CJC-1295 is a modified GHRH analog engineered for extended half-life through Drug Affinity Complex (DAC) technology. Teichman and colleagues (with Ionescu and Frohman), in a 2006 study in the Journal of Clinical Endocrinology and Metabolism, reported dose-dependent increases in GH and sustained IGF-1 elevation following CJC-1295 administration in healthy adults, with prolonged elevation of IGF-1 lasting several weeks after a single injection in higher-dose cohorts. CJC-1295 is frequently compounded in combination with ipamorelin, a selective ghrelin receptor agonist. Raun and colleagues, in the 1998 paper in the European Journal of Endocrinology that first characterized ipamorelin, documented that ipamorelin produces selective GH release without meaningfully elevating cortisol or ACTH — the selectivity profile that makes it preferable to earlier GH secretagogues with off-target effects. Neither CJC-1295 nor ipamorelin is FDA-approved for any indication. Both compounds are currently on FDA's Category 2 bulk drug substances list — designated by FDA as having significant safety concerns that render them ineligible for use in 503A compounding under FDA's interim policy. While some 503A pharmacies have continued to compound these substances under various legal theories, Category 2 compounds are not within FDA's sanctioned 503A pathway under the current interim enforcement posture, and patients accessing these compounds outside the sanctioned pathway assume additional regulatory and clinical risk. [Compounded preparation; no current FDA-approved indication. Both compounds are on FDA's Category 2 bulk drug substances list, meaning they are not eligible for 503A compounding under FDA's interim policy. Any prescribing reflects an independent clinical judgment of the prescribing physician within the constraints of applicable law and regulation.]

Why prescribers choose compounded GH secretagogues over exogenous GH

The rationale for prescribing sermorelin or CJC-1295/ipamorelin rather than exogenous human growth hormone centers on pituitary stimulation versus hormone replacement. Exogenous GH bypasses the hypothalamic-pituitary axis entirely; GH secretagogues stimulate the pituitary to produce GH endogenously, maintaining the pulsatile secretion pattern and the feedback mechanisms that regulate GH levels. A 2006 Endocrine Society guideline authored by Molitch and colleagues in the Journal of Clinical Endocrinology and Metabolism requires IGF-1 testing and clinical assessment before prescribing GH-axis therapies — a standard that applies regardless of whether the compound is an approved GH product or a compounded secretagogue. Prescribers choosing between these options must evaluate the clinical evidence for each approach, the patient's specific deficiency profile, and the regulatory pathway for each compound.

What the Research Does Not Support

BPC-157 as of April 2026

BPC-157 is a synthetic 15-amino-acid peptide fragment studied in preclinical models for effects on soft tissue repair, gut healing, and angiogenesis. BPC-157 has been classified by FDA as a Category 2 bulk drug substance under the 503A interim policy, meaning FDA has identified significant safety concerns that render it ineligible for compounding under the interim policy. Access through 503A pharmacies has been effectively restricted throughout this classification period. The compound has no completed randomized controlled human efficacy trials as of April 2026; the available data is preclinical. Published human data for BPC-157 are limited to small observational reports and case series; no randomized controlled trials have been published in peer-reviewed indexed journals as of 2026. [Preclinical model data only; not available through prescription compounding as of April 2026]

Why Research Peptides Are Not Prescription Peptides

Documented quality failures in the grey market

The fundamental distinction between prescription and research peptides is not regulatory classification alone — it is the documented safety consequence of removing pharmaceutical quality controls. Vanhee and colleagues, in a 2015 analysis in Talanta, analyzed illegal peptide biopharmaceuticals seized from non-prescription channels and documented significant dose inaccuracies and misidentified compounds using LC-MS/MS screening. Janvier and colleagues, in a 2018 analysis in Talanta, found purity ranging from 5% to 75% in falsified polypeptide products and documented arsenic and lead contamination at concentrations up to ten times the ICH toxicity limit for parenteral drugs. Ferrari, in a 2013 review in Revista de la Facultad de Ciencias Medicas (Cordoba), documented harms reported from unsupervised peptide hormone self-administration in the context of performance enhancement. A 2018 analysis by Krug and colleagues (with Thevis) in Growth Hormone & IGF Research identified novel unapproved peptides and unsafe analogs circulating in the black market for performance-enhancing peptides.

Immunogenicity and the case for clinical oversight

Achilleos and colleagues, in a 2025 review in Journal of Peptide Science, examined immunogenicity of FDA-approved peptide therapeutics, including anti-drug antibody formation across injectable peptide drugs. This immunogenicity risk is higher with complex, injectable peptides and with repeated dosing. Clinical detection requires monitoring; a patient obtaining a peptide compound outside the prescription system has no clinical monitoring in place. An adverse immunogenic event in an unsupervised context will not be detected until it becomes symptomatic — and by that point, the clinical response is more limited than it would have been under active monitoring.

Moving a compound from the grey market to the prescription pathway is not simply a matter of obtaining a prescription. The compound must also be eligible for compounding under 503A — meaning it is not on FDA's Category 2 bulk drug substances list and its API source meets FDA requirements. For compounds that are currently Category 2 (including BPC-157, CJC-1295, and ipamorelin as of April 2026), a prescription alone does not create a lawful compounding pathway.

Who Is a Candidate for Prescription Peptide Therapy

Who providers typically evaluate

Providers typically consider prescription peptide therapy for individuals who meet specific clinical criteria that vary by compound class. For GH secretagogues, candidacy typically involves documented or suspected adult GH insufficiency, often indicated by low or low-normal IGF-1 relative to age-adjusted reference ranges, alongside relevant clinical symptoms. For GLP-1 receptor agonists, candidacy for weight management involves BMI above threshold values defined in FDA-approved labeling and relevant comorbidities. Providers typically consider compounded peptide therapy for individuals who:

• Have relevant biomarker values outside the reference range for the compound's target pathway — low IGF-1 for GH secretagogues, elevated glucose and HbA1c for metabolic peptides
• Have relevant clinical symptoms consistent with the compound's proposed mechanism of action
• Have no contraindications to the specific compound class
• Are willing to complete baseline lab evaluation and participate in monitoring during therapy
• Are under the care of a licensed prescriber who can document clinical rationale and manage the prescription

Candidacy assessment requires provider evaluation.

Who should not use prescription peptide therapy

Based on the mechanism of action of compounds in this class, the following groups face elevated risk or are typically excluded from prescription peptide therapy:

• Active or suspected malignancy — growth-promoting peptides may theoretically support tumor proliferation through IGF-1 elevation; GH-axis therapy is generally contraindicated with active cancer
• Pregnancy and breastfeeding — no safety data exists for peptide compounds in these populations; theoretical fetal risk from altered GH axis or metabolic signaling
• Type 1 diabetes or poorly controlled blood glucose — GH secretagogues can impair insulin sensitivity; requires close glucose monitoring if prescribed in the context of metabolic disease
• Known hypersensitivity to any component of the compounded formulation
• Severe renal or hepatic impairment, depending on the specific compound's clearance profile

This is not an exhaustive list. A licensed provider will evaluate individual risk factors, medication interactions, and relevant lab values before prescribing. Contraindications for FDA-approved compounds are defined in the product's prescribing information.

Delivery Methods

Subcutaneous injection

Most prescription compounded peptides are administered by subcutaneous injection. This route provides reliable bioavailability — peptides delivered into the subcutaneous tissue are absorbed into the systemic circulation with reproducible kinetics, avoiding the enzymatic degradation that limits oral bioavailability for most amino acid chain compounds. Walker's 2006 review of sermorelin described the subcutaneous route as the standard clinical delivery method for this compound class. Providers or their clinical staff typically guide first use and injection technique. Any subsequent self-administration occurs under the direction and monitoring of the prescribing provider.

Oral formulations

Oral peptide delivery is constrained by enzymatic degradation in the gastrointestinal tract, which breaks down amino acid chains before systemic absorption can occur. FDA-approved oral semaglutide (Rybelsus) overcomes this through SNAC permeation enhancement technology that enables absorption across the gastric mucosa. Most compounded peptides, including sermorelin and ipamorelin, are not bioavailable by oral route and are administered by injection. Any oral peptide product sold other than FDA-approved oral semaglutide (Rybelsus) should be evaluated critically — the bioavailability claims for unregulated oral peptide products are not supported by the same regulatory evidence base.

Nasal spray

A subset of peptide therapies is available in nasal spray formulation. Bremelanotide was evaluated in intranasal form in clinical trials before the FDA-approved auto-injector formulation was selected. Some providers compound intranasal formulations of PT-141; these are not FDA-approved in that form. Nasal delivery bypasses first-pass metabolism but offers more variable absorption than subcutaneous injection for most peptide classes. Most GH secretagogues are not available in validated nasal formulations with clinical data.

Topical and IV routes

Topical peptide products — creams and serums containing cosmetic peptides — are regulated as cosmetics, not drugs, and have not been FDA-evaluated for systemic therapeutic effects. They are distinct from prescription injectable peptides and not part of the therapeutic prescription pathway. Intravenous peptide infusions are used in clinical settings for select compounds in supervised contexts and are not self-administered routes.

Safety and Side Effects

Side effect profiles vary significantly across the prescription peptide category, from well-characterized FDA-label profiles for approved compounds to emerging data for compounded peptides with smaller evidence bases.

Common side effects (typically mild to moderate, dose-dependent):

• Injection site reactions — redness, swelling, and bruising at the injection site; most common in the initial weeks of therapy and typically self-limiting
• Nausea and gastrointestinal effects — most common with GLP-1 receptor agonists; dose-dependent and typically managed through gradual dose titration
• Transient water retention or peripheral edema — associated with GH-stimulating peptides; generally resolves with dose adjustment under provider supervision
• Headache or mild fatigue — reported in the initial weeks of GH secretagogue therapy

Less common but clinically important:

• IGF-1 elevation above the reference range — associated with GH secretagogue therapy and requires baseline and follow-up IGF-1 monitoring
• Impaired glucose tolerance or insulin resistance — documented with GH-axis peptides; baseline and follow-up HbA1c and fasting glucose are standard monitoring parameters alongside therapy
• Immunogenic reactions including anti-drug antibody formation — Achilleos and colleagues, in a 2025 review in Journal of Peptide Science, examined immunogenicity of FDA-approved peptide therapeutics; risk is higher with injectable, complex peptides and repeated dosing
• Regulatory-status-dependent risks: some compounded peptides carry additional uncertainty because human data is limited relative to the compound's clinical use

Risks specific to unregulated sources:

• Contamination with toxic metals — arsenic and lead contamination was documented in a subset of tested falsified polypeptide products by Janvier and colleagues in 2018, with the highest-contamination samples reaching up to ten times the ICH toxicity limit for parenteral drugs
• Dose inaccuracy — independent testing has identified incorrect dosing and misidentified compounds in non-prescription peptide products
• These risks apply to unregulated grey-market products, not to compounds dispensed by FDA-regulated 503A compounding pharmacies under prescription

When to contact your provider:

• Persistent injection site pain, hardening, or signs of infection — warmth, spreading redness, or fever
• Significant joint pain or severe water retention unresponsive to dose adjustment
• Any unexpected cardiovascular symptoms — chest pain, shortness of breath, or palpitations
• Symptoms consistent with hypoglycemia in patients with pre-existing metabolic conditions

Side effects are typically managed through dose adjustment under the supervision of a licensed provider. The risk profile for any specific compound should be reviewed with a prescribing clinician before starting.

What to Test Before Starting Prescription Peptide Therapy

Establishing a baseline before any peptide prescription is clinically necessary, not optional. Without baseline values, changes during therapy cannot be attributed to the compound, and adverse signals cannot be distinguished from pre-existing patterns. The Endocrine Society guideline for adult GH deficiency authored by Molitch and colleagues requires IGF-1 evaluation before prescribing GH-axis therapies — a minimum standard that prescribing programs should meet or exceed depending on the specific compound and indication.

• IGF-1: The primary pharmacodynamic marker for GH-axis peptides. Testing IGF-1 before starting establishes whether GH insufficiency is clinically present and provides the baseline against which any response can be measured.
• Fasting glucose: GH secretagogues can reduce insulin sensitivity. Baseline fasting glucose documents the glycemic starting point and enables detection of any glucose drift during therapy.
• HbA1c: A 90-day integrated glucose measure. Baseline HbA1c is essential for interpreting glycemic changes that emerge during GH secretagogue therapy.
• eGFR: Kidney function affects drug clearance and is a relevant safety parameter for any injectable peptide therapy. Baseline eGFR documents renal status before initiation.
• Triglycerides and lipid panel: GH secretagogues and GLP-1 agonists both affect lipid metabolism. Baseline triglycerides, LDL, and HDL allow tracking of metabolic response.
• hs-CRP: Baseline hs-CRP documents systemic inflammatory status, relevant context for compounds with anti-inflammatory mechanisms in preclinical models.
• Complete metabolic panel: Liver enzymes, kidney function markers, and electrolytes provide the full safety baseline for any injectable drug regimen.

Understanding your baseline biomarkers is the first step before any peptide therapy evaluation. That principle is central to Superpower's approach to preventive health — objective data before any clinical decision, and ongoing data to interpret response. For a comprehensive overview of the markers relevant to metabolic and hormonal health, the metabolic health biomarker testing guide covers what each marker reveals and why it matters.

What Your Labs May Show During Prescription Peptide Therapy

For growth hormone secretagogue therapy, providers typically monitor IGF-1 as the primary pharmacodynamic marker. An increase toward or within the age-adjusted reference range is consistent with pituitary response; elevation above the upper reference limit is a signal to reduce dose or reassess. The Teichman 2006 CJC-1295 study (with Ionescu and Frohman) reported dose-dependent increases in GH concentration with corresponding IGF-1 elevation — the kind of lab trajectory providers use to assess compound response. Fasting glucose and HbA1c are monitored concurrently for GH-related insulin sensitivity signals; the Endocrine Society recommends reassessment within the first 1 to 3 months of GH-axis therapy. For GLP-1 receptor agonist therapy, glucose and HbA1c trend downward in metabolic responders; lipid panels often show improvement over the first 6 to 12 months; body weight and visceral adiposity are tracked clinically as the primary outcomes.

Members interested in GH secretagogue evaluation can discuss candidacy with a licensed provider; sermorelin prescribing is off-label and is only available when the compound is eligible for 503A compounding at the time of prescribing.

Regulatory Status and Compounding Access

FDA approval status

As of April 2026, FDA-approved prescription peptides with clear approved indications include: semaglutide (type 2 diabetes, chronic weight management, cardiovascular risk reduction), tesamorelin (HIV-associated lipodystrophy only), and bremelanotide (hypoactive sexual desire disorder in premenopausal women). These compounds have defined prescribing information, documented clinical evidence from Phase 3 trials, and commercial pharmacy availability. Compounds including sermorelin, CJC-1295, and ipamorelin are not FDA-approved for any current indication. CJC-1295, ipamorelin, and BPC-157 are on FDA's Category 2 bulk drug substances list under the 503A interim policy, meaning FDA has identified significant safety concerns that render them ineligible for compounding under the interim policy. Sermorelin's compounding eligibility depends on API sourcing and pharmacy compliance rather than a blanket categorical status. Note that 503B outsourcing facilities are a separate compounding pathway that primarily supplies healthcare facilities rather than individual patients; this article focuses on the 503A (individual-patient) pathway.

Compounding access and 503A

As of April 2026, licensed 503A compounding pharmacies may prepare compounded peptide formulations for compounds not on the FDA's restricted lists, pursuant to patient-specific prescriptions from licensed practitioners. The 503A framework requires state pharmacy board licensure, USP Chapter 797 compliance for sterile preparations, and individual patient prescriptions. Pharmacies with PCAB accreditation represent an additional quality credential. Gianturco and Mattingly's foundational analysis of this framework — the 2021 paper distinguishing 503A from 503B facilities published in Journal of the American Pharmacists Association — provides the primary regulatory reference. State-level regulations add additional requirements; the prescriber and compounding pharmacy must both be licensed in the patient's state.

Cost and insurance framing

FDA-approved peptide therapies for approved indications may qualify for insurance coverage with prior authorization; this varies significantly by insurer, plan design, and specific compound. Compounded and off-label formulations are typically not covered by health insurance. HSA and FSA accounts may cover prescription peptide therapy when prescribed by a licensed provider for a documented medical need, though eligibility depends on account type and specific plan rules. Specific compound costs vary and change frequently; any figure cited at time of publication should be verified with the dispensing pharmacy. The evaluation process through a licensed provider includes a clinical consultation and relevant lab work.

How to Evaluate a Provider for Prescription Peptide Therapy

A prescription written without clinical evaluation creates legal access to a compound without the clinical infrastructure — baseline assessment, monitoring, provider accountability — that the prescription pathway is designed to provide. A responsible prescriber for peptide therapy should conduct a full clinical evaluation, review baseline lab data before prescribing, partner with a licensed 503A compounding pharmacy (preferably PCAB-accredited), and maintain a monitoring plan throughout therapy. Dubin and colleagues, in a 2022 review in International Journal of Impotence Research, described a guideline-concordant telemedicine model for testosterone replacement therapy; the same principles (baseline labs, documented clinical rationale, monitoring plan) apply to telehealth peptide prescribing.

Questions to ask before starting with any provider:

• Do you require baseline lab work before prescribing? Which specific markers do you require for this compound?
• How will you monitor my response — what labs, at what intervals, and what values would prompt a dose adjustment?
• Which compounding pharmacy do you use, and does it carry PCAB accreditation or documented USP 797 compliance?
• Is this compound FDA-approved for the indication you are prescribing it for, or is it a compounded preparation without an FDA-approved label? If off-label (use of an approved drug outside its approved indication), what does the evidence base look like and how do you document that clinical rationale? If compounded without an FDA-approved label, is the compound eligible for 503A compounding at your pharmacy today (i.e., not on FDA's Category 2 bulks list and with compliant API sourcing), and what is your documented rationale for choosing a compounded preparation?
• What is the plan if I need to discontinue? Are there tapering considerations for this compound class?

Superpower's provider network requires baseline lab work before prescribing any peptide therapy and includes ongoing biomarker monitoring as part of supervised access.

IMPORTANT SAFETY INFORMATION: This article discusses peptide compounds with varying FDA approval statuses. FDA-approved prescription peptides discussed include semaglutide (Ozempic, Wegovy — FDA-approved for type 2 diabetes and chronic weight management), tesamorelin (Egrifta — FDA-approved for HIV-associated lipodystrophy only), and bremelanotide (Vyleesi — FDA-approved for HSDD in premenopausal women). Compounded peptides discussed — including sermorelin, CJC-1295, and ipamorelin — are not FDA-approved for any indication. As of April 2026, CJC-1295, ipamorelin, and BPC-157 are on FDA's Category 2 bulk drug substances list under the 503A interim policy, meaning FDA has identified significant safety concerns that render them ineligible for compounding under the interim policy. Sermorelin's compounding eligibility depends on API sourcing and pharmacy compliance.

No peptide compound discussed in this article should be self-administered without evaluation and prescription by a licensed healthcare provider. Injectable peptide therapy carries risks including injection site reactions, immunogenic reactions (as examined by Achilleos and colleagues in Journal of Peptide Science 2025 across FDA-approved peptide therapeutics), and GH-related effects on glucose metabolism requiring monitoring. Products obtained outside the 503A prescription-compounding pathway have documented contamination and dose inaccuracy risks.

Superpower connects members with licensed providers who evaluate candidacy, prescribe where appropriate, and monitor response through ongoing lab work. Superpower does not prescribe peptide therapy directly. For prescribing information for FDA-approved compounds, see the DailyMed entries for semaglutide and the DailyMed entries for tesamorelin.

Disclaimer: This page discusses multiple compounds with varying FDA approval statuses. Some compounds mentioned may not be FDA-approved for human use. Superpower Health offers some but not all compounds discussed. See individual compound pages for specific availability and regulatory status. This content is for educational and informational purposes only.